2667 results about "Morpholine" patented technology

The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R1, R2, R3, and R4 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group; X1 represents a C1-6 alkylene group that may be substituted; Xa represents a methoxy group or a fluorine atom; Xb represents an oxygen atom or a methylene group, provided that Xb is only an oxygen atom when Xa is a methoxy group; and Ar1 represents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.

There are disclosed a method for removing CO2 from a combustion exhaust gas which comprises the step of bringing the combustion exhaust gas under atmospheric pressure into contact with an aqueous solution of a hindered amine selected from the group consisting of 2-amino-2-methyl-1-propanol, 2-methylaminoethanol, 2-ethylaminoethanol and 2-piperidineethanol; and another method for removing carbon dioxide from a combustion exhaust gas which comprises the step of bringing the combustion exhaust gas under atmospheric pressure into contact with a mixed aqueous solution of 100 parts by weight of an amine compound (X) selected from the group consisting of 2-amino-2-methyl-1,3-propanediol, 2-amino-2-methyl-1-propanol, 2-amino-2-ethyl-1,3-propanediol, t-butyldiethanolamine and 2-amino-2-hydroxymethyl-1,3-propanediol; and 1-25 parts by weight of an amine compound (Y) selected from the group consisting of piperazine, piperidine, morpholine, glycine, 2-methylaminoethanol, 2-piperidineethanol and 2-ethylaminoethanol.

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6) alkyl, -(C2-C6) alkenyl, or -(C2-C6) alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is -O-; -S(=O)t-, where t is 0, 1, or 2; or -N(R3)-; Y is =C(R1a)-, or -[N<custom-character file="US20020111495A1-20020815-P00900.TIF" wi="20" he="20" id="custom-character-00001" / >(O)k] where k is 0 or 1; R4, R5 and R6 are (1) -H; provided that R5 and R6 are not both -H at the same time, -F; -Cl; -(C2-C4) alkynyl; -R16; -OR16; -S(=O)pR16; -C(=O)R16, -C(=O)OR16, -C(=O)OR<highlight><sup

The present invention belongs to gas producing technology. The absorbing liquid for eliminating sulfide from gas mixture includes main absorbent comprising steric hindrance amine and N-methyl diethanolamine; cosolvent of one or several of sulfolane, N-methyl pyrrolidine, polyglycol dialkyl ether, morpholine and its derivative; catalyst of one or several of C2-C12 alkanolamine, piperazine and its derivative, quinoline, urea and metal phthalocyanine complex. Using the absorbing liquid can eliminate H2S, COS, mercaptan, thioether and other sulfide in less steps.

The present invention relates to heterocyclic compounds represented by the formula I or pharmaceutically acceptable salts thereof and antitumor agents containing the heterocyclic compounds as effective components:wherein X represents nitrogen atom or CH; R1 represents CHnF3-n (wherein n is 1 or 2), hydroxy C1–C6 alkyl, NHR6 [wherein R6 represents hydrogen atom or COR (wherein R represents hydrogen atom, C1–C6 alkyl or C1–C6 alkoxy)]; R2 represents morpholino (which may be substituted with one to four C1–C6 alkyl), thiomorpholino, piperidino, pyrrolidinyl (which may be substituted with hydroxy C1–C6 alkyl), oxazolidinyl (which may be substituted with one or two C1–C6 alkyl) or tetrahydro-1,4-thiazin-1-oxo-4-yl; R3 and R4 each represent hydrogen atom or C1–C6 alkyl; and R5 represents hydrogen atom, amino or hydroxyl.

A method for enhancing, by at least 10 fold, the antibacterial activity of an antisense oligonucleotide composed of morpholino subunits linked by phosphorus-containing intersubunit linkages. The method includes one or both of: conjugating an arginine-rich carrier to a 3′ or 5′ end of the oligonucleotide and modifying the oligonucleotide to contain 20%-50% intersubunit linkages that are positively charged at physiological pH. Also disclosed is an antisense oligonucleotide having enhanced antibacterial activity by virtue of one or both modifications.

The present invention provides a useful morpholino nucleic acid derivative for synthesizing a morpholino nucleic acid oligomer. The present invention provides a compound represented by the following general formula (1) or a salt thereof.Here, R1 represents hydrogen, trityl and so on.R2 represents an amide or an imine.R3 represents a hydroxy group which may be protected by trialkylsilyl and so on, or a group represented by the following general formula (5):(wherein X represents O or S, Y represents dialkylamino or alkoxy, and Z represents chlorine).

A poly(2,6-dimethyl-1,4-phenylene ether) prepared using a morpholine-containing polymerization catalyst has a monomodal molecular weight distribution with a reduced content of very high molecular weight species. It also exhibits increased morpholine incorporation in the high molecular weight fraction. Compared to commercially available poly(2,6-dimethyl-1,4-phenylene ether) prepared using a di-n-butylamine-containing polymerization catalyst, the poly(2,6-dimethyl-1,4-phenylene ether) of the invention exhibits reduced odor. Compared to other poly(2,6-dimethyl-1,4-phenylene ether) prepared using a morpholine-containing polymerization catalyst, the poly(2,6-dimethyl-1,4-phenylene ether) of the invention exhibits improved molecular weight build during compounding and improved compatibilization with polyamides.

An energy beam curable type ink jet printing ink comprising (A) a colorant, (B) a compound having at least one ethylenically unsaturated bond which can be polymerized by the application of an energy beam and (C) a photopolymerization initiator, whereinthe component (B) is a compound having at least one methacryloyl group as a sole polymerizable unsaturated group and the component (C) is a 2-alkyl-2-amino-2-benzyl-1-(4-morpholinophenyl)ethan-1-one.This ink has low viscosity, high sensitivity and sufficiently high film strength after curing.

The use of an N,N-dimethyl alkylamide or an N-alkanoyl morpholine provides a stable emulsifiable concentrate composition that hinders de-esterification and transesterification of mixtures of a carboxylic acid herbicide and an ester of a different carboxylic acid herbicide. The N,N-dimethyl alkylamide or N-alkanoyl morpholine additionally stabilizes emulsifiable concentrates containing a triazolopyrimidine herbicide having at least one methoxy group on the triazolopyrimidine ring.

The invention relates to a preparation method of 4-(3-chlor-4-fluorobenzeneamidocyanogen)-7-methoxy-6-(3-morpholine oxypropyl)quinazoline, which comprises using 3,4-dimethoxybenzoic acid (II) as raw material, synthesizing 2-amido-4-methoxy-5-hydroxybenzoic acid (V), cyclizing to obtain 6-hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one (VI), directly chloridizing to obtain 4-chloro-hydroxy-7-methoxy-quinazoline (VII), reacting directly with 3-chloro-4-fluoroaniline, carrying out amination to obtain 4-(3-chloro-4-fluoroanilino)-6-hydroxy-7-methoxy-quinazoline (VIII), finally reacting with morpholinyl chloropropane to obtain Geftinat (I).

A method for classifying cancer patients as eligible to receive cancer therapy with a small molecule inhibitor of Bcl-2 comprising determination of the presence or absence in a patient tissue sample of chromosomal copy number status at the chromosomal locus 13q14 comprising the microRNA's miR-15a and miR-16-1 or at the chromosomal locus 11q23.1 comprising the microRNA miR-34c. The classification of cancer patients based upon the presence or absence of 13q14 loss or gain allows better selection of patients to receive chemotherapy with a small molecule Bcl-2 inhibitor such as N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl) methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl) methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, and for monitoring patient response to this therapy.

The invention discloses a 4'-carbamate derivative of scutellarin shown in formula (I), a preparation method of the compound and application of the compound in preparing medicines for preventing and / or treating various symptoms and diseases caused by acetyl cholinesterase and / or mediated by free radicals, such as vascular dementia and Alzheimer's disease. In the formula, each of R1, R2 and R3 independently represents H, C1-C12 alkyl or R6CO, wherein R6 represents C1-C12 alkyl, but R1, R2 and R3 are not H at the same time; each of R4 and R5 independently represents H, C1-C12 alkyl, C1-C6 fatty alcohol, or an ester formed by the C1-C6 fatty alcohol and C1-C6 carboxylic acid, the C1-C6 carboxylic acid, or an ester formed by the C1-C6 carboxylic acid and the C1-C6 fatty alcohol; or R4NR5 represents a morpholine ring, a piperidine ring, a 4-benzyl piperidine ring, a piperazine ring, the piperazine ring with the 4-position substituted by C1-C12 alkyl, or a tetrahydropyrrole ring.

The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. Exemplary antisense antiviral compounds are substantially uncharged, or partially positively charged, morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5′ or 3′ terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 30 bases of the 5′ or 3′ terminus of the positive sense vcRNA; c) the 45 bases surrounding the AUG start codon of an influenza viral mRNA and; d) 50 bases surrounding the splice donor or acceptor sites of influenza mRNAs subject to alternative splicing.

Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer, and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.

The invention relates to a hyper-branched polycarboxylate high-efficiency water reducing agent and a preparation method thereof. The water reducing agent is prepared by polymerizing one of tert-butyl acrylate and methyl tert-butyl acrylate with sodium methyl-acryl sulfonate and allyl polyethenoxy ether to form a copolymer main chain, and then performing condensation polymerization on one of acrylic acid and methacrylic acid with ethylene diamine to form a hyper-branched polyamide structure which is grafted to two ends of the main chain. The preparation method comprises the following steps: (1) preparing the sodium methyl-acryl sulfonate into solution with DMF, and heating the solution in a nitrogen atmosphere; (2) dissolving the other two monomers and an initiating agent into the DMF to prepare mixed solution, and dripping the mixed solution into the step (1) to react for 1 to 20 hours; (3) adding a condensating agent CDI after the reaction and performing condensation reaction by using N-methyl morpholine as an organic base, the ethylene diamine and the acrylic acid as the monomers and the DMF as a solvent; and (4) performing vacuum distillation to remove the residual monomers and the solvent, and refluxing for 2 to 5 hours by using methylene chloride solution of trifluoroacetic acid to obtain the water reducing agent. The hyper-branched polycarboxylate water reducing agent has the advantages of low admixture, high water reducing rate, small slump loss, good compatibility with cement, no corrosivity to steel bars, strong frost resistance and the like.

The invention relates to a down jacket cleaning agent which comprises the following components in parts by mass: 1-30 parts of anion surface active agent, 1-15 parts of nonionic surface active agent, 1-10 parts of DP-3000, 0.1-10 parts of tea saponin, 0.1-10 parts of soybean ethyl sulfate morpholine, 0.1-10 parts of ColtideHSi, 0.1-1 part of essence, 0.1-1 part of sodium citrate and 13-97.4 parts of deionized water. The cleaning agent provided by the invention can integrate sterilization, flavor removal and conditioning into a whole and has the advantages of high detergency, high stability, adaptability in cold and hot water and neutrality without damaging hands.

The invention discloses a thifluzamide-containing sterilization composition, and belongs to the technical field of pesticides. The sterilization composition comprises a raw pesticide prepared by compounding a bactericide A and a bactericide B with a ratio of 1-80:1-80; the bactericide A is thifluzamide; and the bactericide B is any one of the following bactericides: a copper preparation, methoxy acrylates, triazoles, amides, benzimidazoles, thiocarbamates, substituted benzenes, pyrroles, dicarboximides, phthalimides, imidazoles, morpholines, carbamates, oxazoles, antibiotics, and the like. The sterilization composition comprises the raw pesticide prepared by compounding a bactericide A and a bactericide B, the sterilization spectrum is expanded, the pesticide resistance of pathogens is alleviated, and the sterilization composition has obvious continuous synergic effect.

The invention discloses a sterilization compound containing chloroisobromine cyanuric acid, comprising a raw medicine formed by compounding a sterilizing agent A and a sterilizing agent B, wherein the proportion of the sterilizing agent A to the sterilizing agent B is (1-80):(1-80); the sterilizing agent A is the chloroisobromine cyanuric acid; and the sterilizing agent B is any one of the following types of the sterilizing agents: copper preparations, methoxy acrylic esters, triazoles, amides, benzimidazoles, thiocarbamates, substituted benzenes, dicarboximides, phthalimides, imidazoles, morpholines, carbamates, oxazoles and the like. The sterilization compound is formed by compounding the sterilizing agent A and the sterilizing agent B so that not only a sterilization spectrum is enlarged, but also the drug resistance of bacteria is slowed; and the sterilization compound has an obvious lasting synergistic effect.

The present invention relates generally to novel processes for covalently conjugating polysaccharides to microspheres or other biomolecules, and more specifically to the use of 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM) in said processes

The invention discloses an imazalil-containing sterilization composition, and belongs to the technical field of pesticides. The sterilization composition comprises a raw pesticide prepared by compounding a bactericide A and a bactericide B with a ratio of 1-80:1-80; the bactericide A is imazalil or efficient imazalil; and the bactericide B is any one of the following bactericides: a copper preparation, methoxy acrylates, triazoles, amides, benzimidazoles, thiocarbamates, substituted benzenes, pyrroles, dicarboximides, phthalimides, imidazoles, morpholines, carbamates, oxazoles, antibiotics, and the like. The sterilization composition comprises the raw pesticide prepared by compounding imazalil or efficient imazalil and a bactericide B, the sterilization spectrum is expanded, the pesticide resistance of pathogens is alleviated, and the sterilization composition has obvious continuous synergic effect.

The present invention provides an improved method for reducing the risk or severity of restenosis following cardiac angioplasty. The method includes administering to a target vessel region, a morpholino antisense compound having a phosphorus-containing backbone linkages, and spanning the start codon of a human c-myc mRNA. Also disclosed are novel antisense compounds and compositions, and a method for assaying the effectiveness of antisense delivery and uptake to a target vessel region.

A cleaning sheet having high cleaning ability and with which finished quality of a surface after cleaning is excellent. A cleaning sheet comprising a sheet base material impregnated with an aqueous cleaning composition that has a pH value of 8 to 11, the composition comprising (A) at least one compound selected from monoethanolamine, morpholine and morpholine derivative compounds, (B) a saturated or unsaturated fatty acid having 14 to 22 carbon atoms, (C) a terpene-type hydrocarbon, and (D) a surfactant.

Pharmaceutical compositions suited for ungual and periungual application and useful for the treatment of dermatological conditions / afflictions, in particular onychomycosis, contain an anti-mycotic agent of the family of the morpholines and a water-soluble film-forming agent.

The present invention discloses the preparation process of Linezolid, and the preparation process includes the following steps: condensation of morpholine and 3, 4-difluoro nitrobenzene; reduction into 3-fluoro-4-morpholinyl aniline under the catalysis of Fe, and acylation with phosgene into 3-fluoro-4-morpholinylphenyl isocyanate; cyclization with (R)-butyl glycidate to produce (R)-N-(3-fluoro-4-morpholinylphenyl)-oxazolone-5-methyl alcohol; and further conventional synthesis steps. The present invention has simple technological process, mild reaction condition, cheap catalyst and low production cost, and is favorable to industrial production.

The process of preparing gefitinib, 4-(3-chloro-4-fluorophenylamido)-7-methoxyl-6-[3-(4- morpholinyl) propoxy] quinazoline, includes following steps: 1. reaction of 3-hydroxy-4-methoxy methyl benzoate as material and 4-(3-chloropropyl) morpholine to obtain 4- methoxyl-3-[3-(4- morpholinyl) propoxy] methyl benzoate; 2. nitration to obtain 2-nitro-4- methoxyl-5-[3-(4- morpholinyl) propoxy] methyl benzoate; 3. reduction to obtain 2-amino-4- methoxyl-5-[3-(4- morpholinyl) propoxy] methyl benzoate; 4. closing cycle to create 7- methoxyl-6-[3-(4- morpholinyl) propoxy] quinazoline-4(3H)-one; 5. chlorinating to obtain 4-chloro-7- methoxyl -6-[3-(4-morpholinyl) propoxy] quinazoline; and 6. reaction to 3-chloro-4-fluoroaniline to obtain gefitinib.

An adhesive sheet includes a substrate and an energy-ray curable adhesive layer formed on the substrate. The energy-ray curable adhesive layer includes an energy-ray curable acrylic copolymer and a urethane acrylate. The energy-ray curable acrylic copolymer is formed by copolymerizing at least one of either a dialkyl(meth)acrylamide that has an alkyl group with carbon number of not more than 4, a phenol EO modified (meth)acrylate that has an ethylene glycol chain with a phenyl group bonded to the ethylene glycol chain, a (meth)acryloyl morpholine, or a (meth)acrylate that has an aceto-acetoxyl group, in total of 1 to 30 weight percent of all monomers to form the energy-ray curable acrylic copolymer. The energy-ray curable acrylic copolymer further includes a side chain with an unsaturated group.